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A bs tr a c t
Background: Structural valve deterioration (SVD) is a major obstacle to lifetime durability for bioprosthetic heart valves. A bio-
prosthetic valve created with RESILIA™ tissue was designed to produce long-term resistance to SVD. 
Aim: The objective of this study was to evaluate the safety and performance of this new class of RESILIA™ tissue aortic bio-
prosthesis.
Methods: A nonrandomised, prospective, multi-centre, single-arm, observational study was performed in 133 patients who 
underwent surgical aortic valve replacement between July 2011 and February 2013. Patients were assessed at 3–6 months 
and one year for haemodynamic performance, clinical outcomes, and functional improvement.
Results: The mean age was 65.3 ± 13.5 years, with 34 (25.6%) of patients < 60 years of age. Early (≤ 30 day) and late (> 30 day) 
all-cause mortality rates were 2.3% (n = 3) and 4.5% (n = 6), respectively. Early events included thromboembolism in three 
(2.3%) patients and major bleeding events requiring transfusion in six (4.5%) patients. Late events included one endocarditis 
leading to explant. Mean gradients were reduced across all valve sizes and were maintained at one year of follow-up. The 
mean effective orifice area and effective orifice area index increased across all valve sizes postoperatively and were maintained 
at one year. The rates of paravalvular leak (> 2+) at 3–6 months and one-year follow-up were 0.7% and 0.7%, respectively.
Conclusions: The new generation RESILIA™ tissue aortic valve bioprosthesis demonstrated excellent haemodynamic per-
formance and safety outcomes at one year of follow-up. Longer follow-up of these patients will provide further insight on 
long-term durability.
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INTRODUCTION
In recent years, in the prosthetic heart valve market there has 
been great heterogeneity of valve sub-models, with different 
post-market surveillance and effectiveness [1]. Therefore, 
replacement of native heart valves with either bioprosthetic 
or mechanical substitutes requires patients and clinicians to 
weigh the impact on long-term quality of life and patient satis-
faction associated with each [2]. Although durable, mechanical 
valves require the use of anticoagulants. In contrast, structural 
valve deterioration (SVD) is a major obstacle to durability for 
bioprosthetic heart valves, limiting their use particularly in 
younger patients [3]. The goal of combining the long-term 
durability of mechanical heart valves with the quality of life 
afforded by bioprosthetic heart valves has been aided by the 
development of advanced technologies aimed at improving 
the long-term durability of bioprosthetic heart valves.
A new class of bioprosthetic valve created with RESILIA™ 
tissue (Edwards Lifesciences LLC, Irvine, CA, USA) has been 
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developed to produce long-term resistance to SVD and im-
prove the durability of bioprosthetic heart valves. RESILIA™ 
tissue is made of bovine pericardium that undergoes two 
distinct treatments based on Edwards Integrity-Preservation 
(EIP™) technology: stable capping, which permanently blocks 
calcium (Ca2+) binding sites and glycerolisation, which protects 
and preserves tissue integrity. In preclinical in vitro and in 
vivo ovine and rabbit studies, RESILIA™ tissue demonstrated 
significantly less Ca2+ accumulation when compared with 
conventional tissue [4, 5]. In addition, initial clinical data on 
the first 20 patients with severe aortic stenosis, who underwent 
isolated aortic valve replacement (AVR) with RESILIA™ tissue 
valves, has demonstrated improved haemodynamic perfor-
mance over baseline values, and durability and safety at up 
to one year of follow-up [6]. Herein we present our further 
results of all 133 patients who underwent AVR with RESILIA™ 
in Poland. Our study present that the use of RESILIA™ tissue 
valves improves haemodynamic and clinical outcomes after 
surgical AVR. Furthermore, the present study encompassed 
a sizeable contingent of younger patients (aged < 60 years), 
which should allow for the long-term follow-up of RESILIA™ 
tissue valve performance.
METHODS
Study design and population
This was a prospective, non-randomised, un-controlled, 
two-centre, single-arm, observational study (Clinical 
Trial number: NCTO 1651052 — Clinical trial of Edwards 
Aortic Bioprosthesis Model 11000, https://clinicaltrials.
gov/ct2/show/NCT01651052), which was designed to as-
sess safety and haemodynamic performance. The study was 
designed by members of the Executive Committee on behalf 
of the study investigators in collaboration with the study 
sponsor, Edwards Lifesciences, LLC. The study protocol was 
reviewed and approved by the Ethics Committee and Polish 
Ministry of Health (CEBK). Inclusion and exclusion criteria 
were described in Table 1.
Patients were offered enrolment into the study by sur-
geons at individual investigational sites. The decision was 
based upon an indication for surgical AVR, an appropriate 
risk profile, and surgical preference for a bioprosthesis. Con-
senting patients were considered enrolled in the study after 
the surgeon visually inspected the aortic root, measured the 
aortic valve annulus, and determined that the study valve 
could be implanted. In each centre RESILIA™ bioprostheses 
were implanted by two trained surgeons. 
A complete one-year follow-up was achieved in 120 of 
133 patients (90.2%). Nine (6.8%) patients had died and four 
(3.0%) patients were not willing to participate further in the 
study and were lost to follow-up.
Baseline characteristics
Between July 2011 and February 2013, a total of 133 patients 
were enrolled in the study, of whom 99 (74.4%) were over 
60 years old, and who required replacement of diseased 
aortic valve. 
Fifty-two (39.1%) patients treated with the study valve 
had isolated aortic stenosis, 25 (18.8%) had isolated aortic 
insufficiency, and 56 (42.1%) had combined aortic valve dys-
function. Echocardiography examinations showed mitral valve 
defects not requiring interventions in 113 patients: in four 
(3.0%) patients mild mitral valve stenosis and in 109 (81.9%) 
mild mitral insufficiency. The patient distribution of the aetiol-
ogy of aortic valve disease was as follows: 93 (69.9%) subjects 
had degenerative valve disease, 24 (18.0%) — dystrophic 
calcification, nine (6.8%) — rheumatic heart disease, and 
18 (13.5%) had other aetiologies. Intraoperative examinations 
showed that two (1.5%) patients had aortic regurgitation due 
to a previous episode of remote endocarditis. In both cases, 
there were no symptoms of infections and inflammatory 
markers were in the normal range. Detailed baseline patient 
characteristics are presented in Table 2.
Study device and surgical procedure
Surgical AVR was performed using the Edwards Aortic Bio-
prosthesis Model 11000A, a trileaflet bioprosthesis identical in 
design to the Carpentier-Edwards PERIMOUNT Magna Ease 
Aortic Valve (Model 3300TFX), except for the tissue technol-
ogy of the leaflet material. The Model 11000A incorporates 
RESILIA™ tissue leaflets created with EIP™ technology, which 
is an advanced tissue technology that preserves tissue integrity 
and is designed to produce consistent long-term resistance to 
SVD by stable capping, which permanently blocks calcium 
Table 1. Inclusion and exclusion criteria
INCLUSION CRITERIA
Age 18 years or above
Written, informed consent prior to trial procedures
Aortic valve disease requiring a planned replacement
With or without concomitant bypass surgery
Willingness to attend all follow-up visits
EXCLUSION CRITERIA
Prior mitral, tricuspid, or pulmonic valve surgery
Need for multiple valve replacement/repair
Aneurysm of the aortic root and/or ascending aorta requiring  
surgical intervention
Active endocarditis/myocarditis within three months of surgery
Renal insufficiency (serum creatinine ≥ 2.5 mg/dL or end stage  
renal disease requiring chronic dialysis) 
MRI or CT scan confirmed stroke, cerebrovascular accident, or  
transient ischaemic attack within six months (180 days) prior to
aortic valve replacement surgery
Acute myocardial infarction within 30 days 
Left ventricular ejection fraction ≤ 30%
CT — computed tomography; MRI — magnetic resonance imaging
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(Ca2+) binding sites [4, 5]. The surgical approach and tech-
nique of implantation was at the discretion of the investigator 
per his/her routine surgical practice and performed via full or 
partial sternotomy using previously described techniques [6]. 
At the discretion of the investigator, bioprosthetic heart valve 
recipients should be maintained on anticoagulant therapy 
(except when contraindicated) during the initial healing 
stages after implant, 2–3 months in accordance with the 
American College of Cardiology/American Heart Association 
2008 Guidelines for the Management of Patients with Valvular 
Heart Disease [7]. Anticoagulants should then be discontinued 
over a period of 10 days, except in those patients for whom 
ongoing anticoagulant treatment is indicated. 
Safety and performance endpoints
Safety endpoints included the following: SVD, thromboembo-
lism, all bleeding/haemorrhage, major bleeding/haemorrhage, 
all paravalvular leak (PVL), major PVL, non-structural valve 
dysfunction, endocarditis, haemolysis, all-cause mortality, 
study valve-related mortality, and explant. SVD included 
dysfunction or deterioration involving the operated valve 
(except infection or thrombosis).
Performance endpoints included clinically acceptable 
haemodynamic performance confirmed by the core lab evalu-
ation of echocardiography, RadCore Labs Torrance, CA, USA. 
Data management
As a study sponsor, Edwards Lifesciences managed the collec-
tion and monitoring of data. Data on adverse events and safety 
outcomes were reviewed and adjudicated by an independent 
Clinical Events Committee.
Statistical analysis
Summary statistics for continuous variables include the 
number of subjects with a value for the variable of interest as 
well as the mean and standard deviation, unless otherwise 
noted. Summary statistics for categorical variables include the 
number and percentage of subjects with a recorded value 
for the variable of interest. Early adverse events, defined as 
occurring within ≤ 30 days of the index procedure, were 
reported as the number of events divided by the number of 
enrolled subjects. Linearised rates were used to summarise 
adverse events for the late (> 30 days) postoperative period. 
The linearised rates were calculated as the number of late 
events divided by the total number of late-subject years with 
one-sided upper 95% confidence limit (CL). Percentages are 
calculated as the number of patients with an event divided 
by the total number of patients receiving the study valve. 
All data were based on a database lock date of March 31, 
2015. Statistical analysis was undertaken using SAS Statistical 
software package version 7.0. 
RESULTS
Procedural outcomes
There were 114 (85.7%) patients who underwent isolated AVR, 
16 (12.0%) who underwent surgery for AVR plus coronary 
artery bypass grafting, and three (2.3%) who were treated 
for AVR plus other concomitant procedures. Of the surgical 
approaches utilised, 117 (88.0%) patients underwent full ster-
notomy and 16 (12.0%) underwent a mini-upper sternotomy. 
Technical success was achieved in all 133 patients on the 
first attempt. Cross-clamp time and cardiopulmonary bypass 
time for isolated AVR cases averaged 61.7 ± 14.4 min and 
96.2 ± 25.6 min, respectively. The average length of stay for all 
Table 2. Baseline characteristics
Age [years]: 65.3 ± 13.5 (22.0–88.0)
< 50 16 (12.0%)
50–60 18 (13.5%)
> 60 99 (74.4%)
Female gender 68 (51.1%)
Race:
Caucasian/white 113 (85.0%)
Not available 20 (15.0%)
Echocardiographic variables:
BMI [kg/m2] 29.3 ± 6.7 (15.8–62.1)
LVEF [%] 61.2 ± 13.7
New York Heart Association:
Class I 28 (21.1%)
Class II 61 (45.9%)
Class III 42 (31.6%)
Class IV 2 (1.6%)
Comorbidities:
Systemic hypertension 105 (78.9%)
Coronary artery disease 64 (48.1%)
Arrhythmia/conduction disturbance 33 (24.8%)
Myocardial infarction 10 (7.5%)
Cerebrovascular disease 7 (5.3%)
Congestive heart failure 3 (2.3%)
Pulmonary hypertension 2 (1.5%)
History of rheumatic fever 8 (6.0%)
Carotid artery disease 6 (4.5%)
Obesity 49 (36.8%)
Diabetes 24 (18.0%)
Renal failure 13 (9.8%)
Chronic pulmonary disease 11 (8.3%)
Peripheral artery or vascular disease 3 (2.3%)
History of smoking 27 (20.3%)
Current smokers 9 (6.8%)
Data are shown as mean ± standard deviation or number (percentage). 
BMI — body mass index; LVEF — left ventricular ejection fraction
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patients was 9.7 ± 5.0 days, with an average of 2.2 ± 2.4 days 
in the intensive care unit (ICU) and 7.6 ± 5.4 days in the 
general ward. 
Usually, if the increased surgical bleeding was reduced, 
oral warfarin was commenced within 24 to 48 h after the 
procedure, and international normalised ratio (INR) was 
maintained at a therapeutic range of 2.0–3.0 for up to three 
months. After three months, the further decision on continu-
ation or discontinuation of anticoagulation treatment was at 
the discretion of the managing physicians.
Safety outcomes
Early primary safety (≤ 30 days) and late (> 30 day) safety 
outcomes are presented in Table 3. Early events included 
all-cause mortality in three (2.3%) patients, thromboembolism 
in three (2.3%), including stroke in two patients and transient 
ischaemic attacks in one patient, and major bleeding events 
requiring transfusion in six (4.5%). The cause of bleeding in 
four patients was anticoagulantion-related haemorrhage. INR 
values in these patients exceeded the therapeutic range. Two 
patients were re-opened for cardiac tamponade and two other 
patients for excessive bleeding (no surgical cause identified) 
within the first month (≤ 30 days). These surgical interventions 
were not related to implanted bioprosthesis. 
One valve was explanted due to endocarditis (> 30 days). 
Post-mortem revealed prosthesis valve thrombosis (PVT) in 
one case.
Haemodynamic outcomes
One case of PVL (> 2+) was observed at 3–6 months in 
a patient with a valve size of 23 mm. Echocardiographic data 
for all subjects stratified by valve size are shown for baseline, 
3–6 months, and one year of follow-up in Table 4. After im-
plantation, there were no statistically significant differences in 
the effective orifice area (EOA), effective orifice area indexed 
to body surface area (EOAi), and mean pressure across all 
valve sizes post-operatively in 3–6 months of follow-up and 
one-year follow-up.
Functional status
New York Heart Association (NYHA) functional class im-
provement was noted in 69.3% of patients at 3–6 months 
of follow-up, whereas 28.3% of patients reported the same 
NYHA functional class as at baseline. At one year postopera-
tively, 95.1% of patients reported the same or improved NYHA 
functional class compared with baseline.
DISCUSSION
The RESILIA™ bioprosthetic heart valve was developed to 
produce consistent long-term resistance to SVD. Early and 
late clinical outcomes and haemodynamic performance of 
RESILIA™ tissue valves were first studied in a series of 20 pa-
tients [6]. The current prospective, multicentre, single-arm 
study extends these previously published observations from 
20 to 133 patients, including 34 young adults under the age 
of 60 years [6]. Data from the current study demonstrate that 
the haemodynamic performance of RESILIA™ tissue valves is 
acceptable and is similar to C-E Perimount valves [8], and C-E 
Perimount Magna Ease [9], with low rates of adverse events at 
one-year follow-up.
Echocardiographic evaluation of overall haemodynamic 
performance at 3–6 months and one year post-implant 
demonstrated a mean EOA of 1.8 ± 0.6 cm2, an EOAi of 
1.0 ± 0.3 and 0.9 ± 0.3 cm2/m2, and a mean pressure gradi-
ent of 12.0 ± 5.7 mmHg and 13.9 ± 6.1 mmHg; obtained 
post-operative haemodynamic parameters were during the 
Table 3. Safety outcomes
Adverse event Early events (≤ 30 days)
na, mb (m/N)
Late events (> 30 days)
nc, mb (m/Late Pt-Yrs)
95% CLd
Mortality 3, 3 (2.3%) 6, 9 (6.8%) 45.8%
Reoperation 0, 0 (0.0%) 1, 1 (0.7%) 1.5%
Explante 0, 0 (0.0%) 1, 1 (0.7%) 1.5%
Thromboembolism 3, 3 (2.3%) 1, 1 (0.7%) 1.5%
Major bleeding event requiring transfusion 6, 6 (4.5%) 0, 0 (0.0%) 1.2%
Paravalvular leak major 1, 1 (0.7%) 0, 1 (0.7%) 1.5%
Endocarditis 0, 0 (0.0%) 1, 1 (0.7%) 1.5%
Structural valve deterioration 0, 0 (0.0%) 0, 0 (0.0%) 1.5%
an — ‘n’ is the number of subjects who experienced the specific type of adverse events ≤ 30 days.
bm —  ‘m’ is the number of specific adverse events observed.
cn — ‘n’ is the number of subjects who experienced the specific type of adverse events > 30 days.
d95% CL is the one-sided upper 95% confidence limit for the linearised rate.
eExplant due to endocarditis occurred in one patient.
Pt-Yrs — patient-years
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whole follow-up period. The rate of moderate or severe PVL 
was 0.7% and 0.0%, respectively. Furthermore, improve-
ment or no change in NYHA functional class was observed 
in > 95.1% of patients at one year of follow-up.
Currently available heart valve substitutes are either me-
chanical or bioprosthetic; however, neither option provides 
an ideal substitute for the native heart valve [10]. Mechanical 
valves, which are usually recommended for younger patients, 
provide superior long-term durability compared with biopros-
thetic valves, but require strict anticoagulation prophylaxis, 
which increases the risk of major bleeding. On the other 
hand, bioprosthetic valves are a reasonable option for patients 
who wish to avoid long-term anticoagulation. In patients with 
surgical aortic bioprostheses, the use of low-dose aspirin is 
now favoured as an alternative to postoperative anticoagu-
lant therapy [11]. However, bioprosthetic valves are prone 
to structural degradation over time [8, 12]. Underlying both 
treatment options is patient prognosis, which depends in part 
on durability, valve haemodynamic performance, potential 
risks and complications, and the potential need for chronic 
anticoagulation therapy [10, 13]. 
In our study, there was one (0.7%) case of PVT discovered 
in post-mortem examination. The incidence of PVT observed 
in bioprosthetic heart valve is around 1.2% [11]. The type of 
bioprosthesis also appears to influence the risk of PVT; thus, 
the risk of thrombosis is higher with stented than with stent-
less bioprostheses, and the risk of PVT is highest in the first 
three months after implantation [11, 14]. Therefore, we sug-
gest that the prevalence of PVT after RESILIA™ tissue valve 
implantation is acceptable.  
The average length of stay on ICU was 2.2 days, and 
7.6 days in the general ward. The discharge of patients from 
the ICU to the postoperative ward was determined by the 
patient’s health status assessed by the Therapeutic Intervention 
Scoring System (score between 0 and 19 points; TISS-28) of 
cardiac surgical postoperative intensive care and by the clinical 
judgment of the physician discharging the patient from the ICU. 
No fast-track or early extubation anaesthetic techniques were 
used [15]. Compared with other bioprosthesis studies [16], 
RESILIA™ valves demonstrated a slightly lower ICU and overall 
length of hospital stay.
The primary mechanism of failure of the bioprosthetic 
heart valve implantation is SVD, a process in which biolog-
ically-derived valvular leaflet tissue undergoes calcification 
over time, leading to stiffening and tearing [3]. Risk factors 
associated with the incidence of SVD include patient age at 
the time of implant, arterial hypertension, diabetes, cigarette 
smoking, hypercholesterolaemia, and chronic renal failure 
[17]. Although numerous cellular and molecular processes 
are thought to contribute to the calcification process, residual 
phospholipid and aldehyde moieties in processed biopros-
thetic valve leaflets are important contributors to the formation 
of calcium phosphate crystals [18, 19].
Additional factors that affect the rate of calcification are: 
the size of the implanted bioprosthesis, whether the patient 
experiences Patient-Prosthesis Mismatch (PPM), and the amount 
of mechanical stress the valve experiences in vivo [20, 21]. 
Consequently, the use of systemically administered phar-
macological agents or localised treatment strategies utilising 
anti-calcification agents or tissue treatment approaches have 
been investigated as potential inhibitors of calcification [22, 
23]. To this end, RESILIA™ tissue valves combine two features 
that are unique: stable capping that permanently blocks 
Ca2+ binding sites, and glycerolisation that preserves tissue 
integrity by displacing the water in the pericardial tissue with 
glycerol [24].
Preclinical in vitro and in vivo studies of RESILIA™ tissue 
bioprosthesis have been encouraging. Valve function and dura-
bility have been evaluated in a prospective, randomised study 
involving juvenile sheep, where RESILIA™ mitral valves were 
Table 4. Echocardiographic data by valve size at follow-up
Parameter Follow-up 19 mm  
(n = 12)
21 mm  
(n = 46)
23 mm 
(n = 41)
25 mm 
(n = 24)
27 mm 
(n = 10)
Total  
(n = 133)
EOA [cm2] Baseline 0.8 ± 0.2 (12) 0.8 ± 0.3 (45) 0.9 ± 0.5 (40) 1.5 ± 1.3 (23) 1.8 ± 1.1 (10) 1.0 ± 0.8 (130)
3–6 months 1.4 ± 0.4 (12) 1.7 ± 0.4 (43) 1.9 ± 0.4 (37) 2.1 ± 0.7 (24) 2.3 ± 0.5 (10) 1.8 ± 0.5 (126)
1 year 1.2 ± 0.3 (12) 1.6 ± 0.5 (39) 1.9 ± 0.7 (37) 2.0 ± 0.7 (21) 2.1 ± 0.3 (10) 1.8 ± 0.6 (119)
EOAi [cm2/ m2] Baseline 0.4 ± 0.1 (12) 0.4 ± 0.2 (37) 0.5 ± 0.2 (30) 0.8 ± 0.7 (21) 0.9 ± 0.6 (9) 0.6 ± 0.4 (109)
3–6 months 0.8 ± 0.3 (12) 1.0 ± 0.3 (35) 1.0 ± 0.3 (29) 1.1 ± 0.4 (22) 1.1 ± 0.3 (9) 1.0 ± 0.3 (107)
1 year 0.7 ± 0.2 (12) 0.9 ± 0.3 (32) 1.0 ± 0.4 (29) 1.0 ± 0.4 (19) 1.0 ± 0.2 (9) 0.9 ± 0.3 (101)
Mean gradient  
[mmHg]
Baseline
3–6 months
49.2 ± 16.4 (12)
20.0 ± 11.1 (12)
54.0 ± 20.8 (46)
12.0 ± 4.6 (43)
50.6 ± 21.6 (41)
11.1 ± 3.9 (39)
43.5 ± 24.0 (24)
10.8 ± 3.5 (24)
38.0 ± 22.6 (10)
8.8 ± 3.5 (10)
49.4 ± 21.7 (133)
12.0 ± 5.7 (128)
1 Year 21.7 ± 9.5 (12) 14.2 ± 4.9 (40) 12.0 ± 4.3 (37) 13.8 ± 3.5 (21) 11.1 ± 4.5 (10) 13.9 ± 6.1 (120)
Data are shown as mean ± standard deviation and (number). EOA — effective orifice area; EOAi — effective orifice area indexed to body surface 
area
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compared with PERIMOUNT valves, which have demonstrated 
a 25-year durability [5, 25]. At eight months of follow-up, 
RESILIA™ mitral valves had significantly less Ca2+ content 
than PERIMOUNT valves, as confirmed by radiographic and 
histological analyses (1.9 ± 0.3 µg/mg vs. 6.8 ± 1.6 µg/mg, 
p = 0.002) [5]. Similarly, in a rabbit model in which tissue 
discs were implanted intramuscularly, there was significantly 
lower Ca2+ content at 60 days in RESILIA™ tissue compared 
with bovine tissue treated with XenoLogicX [4, 26]. Overall, 
these results from in vitro and in vivo studies support the 
view that RESILIA™ bioprostheses show significantly less 
Ca2+accumulation compared with conventional bioprosthe-
ses. For patients reaching the one-year follow-up points in 
our study, no SVD was observed in any patient.
When compared with other valves evaluated at similar 
follow-up periods, the haemodynamic performance of the 
RESILIA™ tissue valve was consistent with outcomes from other 
studies involving Carpentier-Edwards valves [27].
In a subsequent 2011 report, Mosaic valves demon-
strated a one-year overall mean pressure gradient and EOA 
of 17.1 ± 8.2 mmHg and 1.69 ± 0.40 cm2, respectively [28]. 
Compared with these studies, RESILIA™ valves demonstrated 
a numerically lower overall mean pressure gradient and larger 
EOA, 13.9 ± 6.1 mmHg and 1.8 ± 0.6 cm2, respectively. 
Moreover, the Epic bioprosthetic valve at one year dem-
onstrated a mean pressure gradient of 15.3 ± 6.5 mmHg 
and EOAi of 0.67 ± 0.2 cm2/m2, again suggesting superior-
ity of the RESILIA™ valve with a one-year EOAi of mean 
0.9 ± 0.3 cm2/m2 [16]. However, at one year the EOAi for a 19-
mm valve is noted to be 0.7 ± 0.2 (n = 12). This may be due 
to the small number of patients, and physical characteristics 
(small annulus in a large patient) may have played a role. 
When compared with the results of a recent study by Wendt 
et al. [9], which reported the mean pressure gradients of the 
Trifecta, Magna, and Magna Ease bioprosthetic valves, the 
RESILIA™ values implanted in the present study appeared to 
be comparable. Finally, in patients with a small aortic annulus, 
a population at higher risk for prosthesis-patient mismatch, 
at one year the RESILIA™ demonstrated a mean EOAi of 
0.7 ± 0.2 (n = 12) for the 19-mm valve, with no incidence 
of severe PPM, which is larger than the reported EOAi for 
the 19-mm Mosaic Ultra valve (0.66 ± 0.15 cm2/m2 at 
6.5 ± 4.0 months of follow-up) [29]. For the overall group, the 
EOAi was 0.9 ± 0.3 (101) with no incidence of severe PPM.
Finally, when selecting an appropriate bioprosthetic 
valve, the age of the patient is the most important predictor of 
SVD. Bourguignon et al. [30], reported that patients receiving 
a PERIMOUNT aortic valve experienced markedly different 
rates of reoperation for SVD depending on their age at the 
time of the index procedure. Indeed, a 50-year-old patient 
had a 20% probability of reoperation after 15 years, whereas 
a 70-year-old patient had only a 5% probability of reopera-
tion. Similarly, Johnston et al. [20] confirmed the relationship 
between the risk of reoperation for SVD and patient age at 
implant. However, when comparing the survival of patients 
receiving mechanical vs. bioprosthetic valves, Chiang et al. [2] 
have recently reported no difference in 15-year survival or 
stroke in a retrospective analysis of 4253 propensity-matched 
patients aged 50–69 years, who underwent AVR. Also, patients 
in the bioprosthetic valve group had a greater likelihood of 
reoperation but a lower likelihood of major bleeding. Thus, 
the authors concluded that the lack of a significant difference 
in mortality suggests bioprostheses may be a reasonable alter-
native to mechanical valves in younger patients. 
Limitations of the study
This study was single-arm with non-consecutive enrolment, 
and there was no active comparator group. Hence,  selec-
tion bias cannot be excluded. Additional randomised con-
trolled studies will be necessary in the future to compare the 
RESILIATM with other valves. The number of patients who 
received 19-mm valves in this series is quite small and hence 
it will be difficult to assess the incidence of severe PPM. Also, 
assumptions of durability are limited because this study reports 
the safety and efficacy outcomes at one year. 
CONCLUSIONS
Structural valve deterioration is a major obstacle to lifetime 
durability for bioprosthetic heart valves, particularly in younger 
patients. In this report on 133 patients, which includes 
34 young adults under the age of 60 years, a new genera-
tion RESILIA™ tissue aortic valve bioprosthesis demonstrated 
excellent haemodynamic performance and safety outcomes 
at one-year follow-up. Longer follow-up of these patients will 
provide further insight on the long-term durability of RESILIA™ 
tissue bioprosthetic heart valves. Patients from the multicentre 
COMMENCE trial will be followed and assessed after Edwards 
Aortic Bioprosthesis Model 11000 with RESILIA™ tissue im-
plantation for up to five years.
Funding: This study was performed with financial and technical 
support (medical devices — valves) from Edwards Lifesciences 
Inc. (Irvine, CA, USA) to both Institutions.
Conflict of interest: none declared
References
1. Hickey GL, Bridgewater B, Grant SW, et al. National Registry 
Data and Record Linkage to Inform Postmarket Surveillance of 
Prosthetic Aortic Valve Models Over 15 Years. JAMA Intern Med. 
2017; 177(1): 79–86, doi:  10.1001/jamainternmed.2016.6936, 
indexed in Pubmed: 27820610.
2. Chiang YP, Chikwe J, Moskowitz AJ, et al. Survival and long-term 
outcomes following bioprosthetic vs mechanical aortic valve 
replacement in patients aged 50 to 69 years. JAMA. 2014; 
312(13): 1323–1329, doi: 10.1001/jama.2014.12679, indexed in 
Pubmed: 25268439.
3. Grunkemeier GL, Furnary AP, Wu Y, et al. Durability of pericardi-
al versus porcine bioprosthetic heart valves. J Thorac Cardiovasc 
www.kardiologiapolska.pl
Krzysztof Bartuś et al.
624
Surg. 2012; 144(6): 1381–1386, doi: 10.1016/j.jtcvs.2012.08.060, 
indexed in Pubmed: 23010581.
4. De La, Wright GA, Olin JM, et al. Advanced Integrity Preserva-
tion Technology Reduces Bioprosthesis Calcification While 
Preserving Performance and Safety. J Heart Valve Dis. 2015; 
24(1): 101–109, indexed in Pubmed: 26182627.
5. Flameng W, Hermans H, Verbeken E, et al. A randomized as-
sessment of an advanced tissue preservation technology in 
the juvenile sheep model. J Thorac Cardiovasc Surg. 2015; 
149(1): 340–345, doi: 10.1016/j.jtcvs.2014.09.062, indexed in 
Pubmed: 25439467.
6. Sadowski J, Bartuś K, Kapelak B, et al. Aortic valve replacement 
with a novel anti-calcification technology platform. Kardiol Pol. 
2015; 73(5): 317–322, doi: 10.5603/KP.a2014.0214, indexed in 
Pubmed: 25371311.
7. Bonow RO, Carabello BA, Chatterjee K, et al. American Col-
lege of Cardiology/American Heart Association Task Force on 
Practice Guidelines. 2008 focused update incorporated into the 
ACC/AHA 2006 guidelines for the management of patients with 
valvular heart disease: a report of the American College of Cardi-
ology/American Heart Association Task Force on Practice Guide-
lines (Writing Committee to revise the 1998 guidelines for the 
management of patients with valvular heart disease). Endorsed 
by the Society of Cardiovascular Anesthesiologists, Society for 
Cardiovascular Angiography and Interventions, and Society of 
Thoracic Surgeons. J Am Coll Cardiol. 2008; 52(13): e1–e142, 
doi: 10.1016/j.jacc.2008.05.007, indexed in Pubmed: 18848134.
8. Nishida T, Sonoda H, Oishi Y, et al. Long-term results of aortic 
valve replacement with mechanical prosthesis or carpentier-ed-
wards perimount bioprosthesis in Japanese patients according to 
age. Circ J. 2014; 78(11): 2688–2695, doi: 10.1253/circj.cj-14-0466, 
indexed in Pubmed: 25262964.
9. Wendt D, Thielmann M, Plicht B, et al. The new St Jude Trifecta 
versus Carpentier-Edwards Perimount Magna and Magna Ease 
aortic bioprosthesis: is there a hemodynamic superiority? 
J Thorac Cardiovasc Surg. 2014; 147(5): 1553–1560, doi: 10.1016/j.
jtcvs.2013.05.045, indexed in Pubmed:23870159.
10. Wu Y, Butchart EG, Borer JS, et al. Clinical evaluation of new 
heart valve prostheses: update of objective performance criteria. 
Ann Thorac Surg. 2014; 98(5): 1865–1874, doi: 10.1016/j.atho-
racsur.2014.05.006, indexed in Pubmed: 25258160.
11. Nishimura RA, Otto CM, Bonow RO, et al. ACC/AHA Task 
Force Members. 2014 AHA/ACC Guideline for the Management 
of Patients With Valvular Heart Disease: executive summary: 
a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines. Circulation. 
2014; 129(23): 2440–2492, doi: 10.1161/CIR.0000000000000029, 
indexed in Pubmed: 24589852.
12. Vesey JM, Otto CM. Complications of prosthetic heart valves. Curr 
Cardiol Rep. 2004; 6(2): 106–111, doi:  10.1007/s11886-004-
0007-x, indexed in Pubmed: 14759353.
13. Blauwet LA, Miller FA. Echocardiographic assessment of pros-
thetic heart valves. Prog Cardiovasc Dis. 2014; 57(1): 100–110, 
doi:10.1016/j.pcad.2014.05.001, indexed in Pubmed: 25081405.
14. Dangas GD, Weitz JI, Giustino G, et al. Prosthetic Heart Valve 
Thrombosis. J Am Coll Cardiol. 2016; 68(24): 2670–2689, 
doi: 10.1016/j.jacc.2016.09.958, indexed in Pubmed: 27978952.
15. Litwinowicz R, Bartus K, Drwila R, et al. In-hospital mortality 
in cardiac surgery patients after readmission to the intensive 
care unit: a single-center experience with 10,992 patients. 
J Cardiothorac Vasc Anesth. 2015; 29(3): 570–575, doi: 10.1053/j.
jvca.2015.01.029, indexed in Pubmed: 26009285.
16. Bobiarski J, Newcomb AE, Elhenawy AM, et al. One-year 
hemodynamic comparison of Perimount Magna with St Jude 
Epic aortic bioprostheses. Arch Med Sci. 2013; 9(3): 445–451, 
doi: 10.5114/aoms.2013.35479, indexed in Pubmed: 23847665.
17. Mohammadi S, Tchana-Sato V, Kalavrouziotis D, et al. Long-term 
clinical and echocardiographic follow-up of the Freestyle stent-
less aortic bioprosthesis. Circulation. 2012; 126(11 Suppl 1): 
S198–S204, doi:  10.1161/CIRCULATIONAHA.111.084806, 
indexed in Pubmed: 22965983.
18. Perrotta I, Davoli M. Collagen mineralization in human aortic 
valve stenosis: a field emission scanning electron microscopy and 
energy dispersive spectroscopy analysis. Ultrastruct Pathol. 2014; 
38(4): 281–284, doi: 10.3109/01913123.2014.901468, indexed in 
Pubmed: 24833324.
19. Schoen FJ, Levy RJ. Calcification of tissue heart valve substi-
tutes: progress toward understanding and prevention. Ann 
Thorac Surg. 2005; 79(3): 1072–1080, doi: 10.1016/j.athorac-
sur.2004.06.033, indexed in Pubmed: 15734452.
20. Johnston DR, Soltesz EG, Vakil N, et al. Long-term durability 
of bioprosthetic aortic valves: implications from 12,569 im-
plants. Ann Thorac Surg. 2015; 99(4): 1239–1247, doi: 10.1016/j.
athoracsur.2014.10.070, indexed in Pubmed: 25662439.
21. Urso S, Calderón P, Sadaba R, et al. Patient-prosthesis mismatch 
in patients undergoing bioprosthetic aortic valve implantation 
increases risk of reoperation for structural valve deterioration. 
J Card Surg. 2014; 29(4): 439–444, doi: 10.1111/jocs.12345, 
indexed in Pubmed: 24773571.
22. Chen W, Schoen FJ, Levy RJ. Mechanism of efficacy of 2-amino oleic 
acid for inhibition of calcification of glutaraldehyde-pretreated por-
cine bioprosthetic heart valves. Circulation. 1994; 90(1): 323–329, 
doi: 10.1161/01.cir.90.1.323, indexed in Pubmed: 8026014.
23. Vyavahare N, Hirsch D, Lerner E, et al. Prevention of bioprosthetic 
heart valve calcification by ethanol preincubation. Efficacy and 
mechanisms. Circulation. 1997; 95(2): 479–488, doi: 10.1161/01.
cir.95.2.479, indexed in Pubmed: 9008467.
24. Tanzer ML. Intermolecular cross-links in reconstituted collagen 
fibrils. Evidence for the nature of the covalent bonds. J Biol Chem. 
1968; 243(15): 4045–4054, indexed in Pubmed: 5666947.
25. Bourguignon T, Bouquiaux-Stablo AL, Loardi C, et al. Very 
late outcomes for mitral valve replacement with the Carpen-
tier-Edwards pericardial bioprosthesis: 25-year follow-up of 
450 implantations. J Thorac Cardiovasc Surg. 2014; 148(5): 
2004–2011.e1, doi:  10.1016/j.jtcvs.2014.02.050, indexed in 
Pubmed: 24667021.
26. Wright GA, Faught JM, Olin JM. Assessing anticalcification treat-
ments in bioprosthetic tissue by using the New Zealand rabbit 
intramuscular model. Comp Med. 2009; 59(3): 266–271, indexed 
in Pubmed: 19619417.
27. Dalmau MJ, María González-Santos J, López-Rodríguez J, et 
al. One year hemodynamic performance of the Perimount 
Magna pericardial xenograft and the Medtronic Mosaic 
bioprosthesis in the aortic position: a prospective randomized 
study. Interact Cardiovasc Thorac Surg. 2007; 6(3): 345–349, 
doi:10.1510/icvts.2006.144196, indexed in Pubmed: 17669862.
28. Dalmau MJ, González-Santos JM, Blázquez JA, et al. Hemody-
namic performance of the Medtronic Mosaic and Perimount 
Magna aortic bioprostheses: five-year results of a prospectively 
randomized study. Eur J Cardiothorac Surg. 2011; 39(6): 844–52; 
discussion 852, doi:  10.1016/j.ejcts.2010.11.015, indexed in 
Pubmed: 21193320.
29. Okamura H, Yamaguchi A, Yoshizaki T, et al. Clinical out-
comes and hemodynamics of the 19-mm Perimount Magna 
bioprosthesis in an aortic position: comparison with the 19-mm 
Medtronic Mosaic Ultra Valve. Circ J. 2012; 76(1): 102–108, 
doi: 10.1253/circj.cj-11-0728, indexed in Pubmed: 22094910.
30. Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, et al. Very 
long-term outcomes of the Carpentier-Edwards Perimount 
valve in aortic position. Ann Thorac Surg. 2015; 99(3): 
831–837, doi:  10.1016/j.athoracsur.2014.09.030, indexed in 
Pubmed: 25583467.
Cite this article as: Bartuś K, Litwinowicz R, Kuśmierczyk M, et al. Primary safety and effectiveness feasibility study after surgical aortic 
valve replacement with a new generation bioprosthesis: one-year outcomes. Kardiol Pol. 2018; 76(3): 618–624, doi: 10.5603/KP.a2017.0262.
